skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer

Review

(2725) Views  (633) Full article downloads

Authors: Jochen H Lorch

Published Date November 2009 Volume 2009:1 Pages 151 - 154
DOI: http://dx.doi.org/10.2147/CMAR.S5134

Jochen H Lorch

Dana Farber Cancer institute, Boston, MA, USA

Abstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments.

Keywords: squamous cell cancer, head, neck, epidermal growth factor receptor








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Validation of the cell cycle G2 delay assay in assessing ionizing radiation sensitivity and breast cancer risk
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies
Erratum
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University